Project Number 5U01AG010483-18 Agency/Funding Organization NIA Funding Year 2008 View Full Project Details for A TRIAL OF TTP488 TO SLOW THE RATE OF CLINICAL PROGRESSION OF PATIENTS WITH AD Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 7. Early-stage Clinical Drug Development (Phase I and II Clinical Trials) r. Multi-target Category G. Consortia and Public Private Partnerships 1. Consortia Researcher and Organization Principal Investigator GALASKO, DOUGLAS R Principal Investigator First Name DOUGLAS Principal Investigator Last Name GALASKO Awardee Organization UNIVERSITY OF CALIFORNIA SAN DIEGO Awardee State California Contact PI Country United States Project Detail FY Overall Cost $1,517,318 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official RYAN, LAURIE M Special Initiative Alzheimer's Disease Cooperative Study (ADCS) Related Resources Repository [NIAGADS] Transethnic GWAS Summary Statistics - Jun et al. (2017) [NIAGADS] ADGC African American Summary Statistics- Reitz et al. (2013) [NIAGADS] ADGC Neuropath Summary Stats and Phenotypes- Beecham et al. (2014) [NIAGADS] ADGC Summary Statistics- Naj et al. (2011) [AlzPED] CRF receptor-1 antagonism mitigates Aβ pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease [AlzPED] Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model. [AlzPED] Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model. Clinical Trial Effects of Atomoxetine in Mild Cognitive Impairment Estrogen Hormone Protocol Multicenter Trial of Prednisone in Alzheimer's Disease Pagination Page 1 Next page ››
